Skip to main content
Equibles
CVRX logo

CVRX · CVRx, Inc.

Track CVRX — free

Use CVRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CVRX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.08 +0.14 (+4.76%) At close · Aug 14
Market Cap
$82.06M
Shares
26.64M

CVRx, Inc. Earnings Call Transcripts

Every quarterly earnings call for CVRx, Inc. (CVRX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲82.2% $6.19M −$9.83M '22 Q3 22-11-01 ▲96.2% $7.18M −$10.54M '22 Q4 23-01-26 ▲95.8% $7.98M −$11.37M '23 Q1 23-04-27 ▲88.8% $9.50M −$11.65M '23 Q2 23-07-25 ▲69.9% $10.51M −$9.01M '23 Q3 23-10-26 ▲57.5% $11.30M −$9.16M '23 Q4 24-01-25 ▲35% $10.77M −$22.19M '24 Q1 24-04-30 ▲24.3% $11.81M −$14.03M '24 Q2 24-07-29 ▲27.2% $13.37M −$13.10M '24 Q3 24-10-29 ▲35.7% $15.34M −$10.65M '24 Q4 25-01-13 ▲14.7% $12.35M −$13.77M '25 Q1 25-04-07 ▲15.1% $13.59M −$14.74M '25 Q2 25-08-04 ▲9.8% $14.69M −$12.87M '25 Q3 25-11-05 ▲4.4% $16.02M −$11.93M '25 Q4 26-02-12 ▲19.6% $14.77M −$13.12M '26 Q1 26-05-11 LATEST ▲15.6% $15.71M −$14.04M '26 Q2 26-08-06
Conference
Investor event
2026-08-11
Canaccord Genuity's 46th Annual Growth Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
CVRx Q2 2026 Earnings Call
Cautious tone Salesforce turnover and productivity Reimbursement progress and payment rates Medicare Advantage prior authorization headwinds
Revenue
$15.71M
▲ 15.6% YoY
Diluted EPS
$-0.53
Gross margin
87.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-10
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-02
William Blair 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-11
CVRx, Inc. Q1 FY2026 Earnings Call
Confident tone Reimbursement progress with Category 1 CPT codes Medicare Advantage prior authorization disruption U.S. revenue growth and sales expansion
Revenue
$14.77M
▲ 19.6% YoY
Diluted EPS
$-0.50
Gross margin
87.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
CVRx, Inc. Q4 FY2025 Earnings Call
Positive tone Revenue growth and commercial investment Barostim therapy and market opportunity Category 1 CPT code transition
Revenue
$16.02M*
▲ 4.4% YoY
Gross margin
86.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
CVRx, Inc. Q3 FY2025 Earnings Call
Confident tone 2026 operating expense leverage Revenue and financial performance Q4 guidance and conservatism
Revenue
$14.69M
▲ 9.8% YoY
Diluted EPS
$-0.49
Gross margin
86.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
CVRx, Inc. Q2 FY2025 Earnings Call
Confident tone Revenue growth and quarterly results Adoption barriers and war of attrition Reimbursement progress
Revenue
$13.59M
▲ 15.1% YoY
Diluted EPS
$-0.57
Gross margin
84.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-07
CVRx, Inc. Q1 FY2025 Earnings Call
Balanced tone Targeting sustainable centers and program-focused selling Physician awareness and conferences Barostim therapy and market opportunity
Revenue
$12.35M
▲ 14.7% YoY
Diluted EPS
$-0.53
Gross margin
83.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
CVRx, Inc. Q4 FY2024 Earnings Call
Confident tone U.S. Heart Failure Revenue Growth Reimbursement and CPT Coding Patient Access and Prior Authorization
Revenue
$15.34M*
▲ 35.7% YoY
Gross margin
83.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-29
CVRx, Inc. Q3 FY2024 Earnings Call
Confident tone Barostim therapy adoption and standard-of-care Reimbursement wins (DRG and CPT codes) Revenue growth and commercial execution
Revenue
$13.37M
▲ 27.2% YoY
Diluted EPS
$-0.57
Gross margin
83.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-29
CVRx, Inc. Q2 FY2024 Earnings Call
Positive tone U.S. Heart Failure business and Barostim adoption CMS outpatient reimbursement (OPPS proposed rule) Patient access, education, and direct-to-consumer outreach
Revenue
$11.81M
▲ 24.3% YoY
Diluted EPS
$-0.65
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
CVRx, Inc. Q1 FY2024 Earnings Call
Balanced tone Barostim market opportunity and penetration New CEO transition and background Go-to-market priorities: awareness, evidence, access
Revenue
$10.77M
▲ 35% YoY
Diluted EPS
$-1.04
Gross margin
85.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-25
CVRx, Inc. Q4 FY2023 Earnings Call
Confident tone Guidance and Cash Discipline CEO Succession and Leadership Transition Revenue Growth and Barostim Adoption
Revenue
$11.30M*
▲ 57.5% YoY
Gross margin
84.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-26
CVRx, Inc. Q3 FY2023 Earnings Call
Revenue
$10.51M
▲ 69.9% YoY
Diluted EPS
$-0.43
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-25
CVRx, Inc. Q2 FY2023 Earnings Call
Revenue
$9.50M
▲ 88.8% YoY
Diluted EPS
$-0.56
Gross margin
84.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
CVRx, Inc. Q1 FY2023 Earnings Call
Revenue
$7.98M
▲ 95.8% YoY
Diluted EPS
$-0.55
Gross margin
83.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-26
CVRx, Inc. Q4 FY2022 Earnings Call
Revenue
$7.18M*
▲ 96.2% YoY
Gross margin
79.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
CVRx, Inc. Q3 FY2022 Earnings Call
Revenue
$6.19M
▲ 82.2% YoY
Diluted EPS
$-0.48
Gross margin
78.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
CVRx, Inc. Q2 FY2022 Earnings Call
Revenue
$5.03M
▲ 61.1% YoY
Diluted EPS
$-0.54
Gross margin
76.1%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-25
CVRx, Inc. Q1 FY2022 Earnings Call
Revenue
$4.08M
▲ 42.5% YoY
Diluted EPS
$-0.49
Gross margin
76.7%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
CVRx, Inc. Q4 FY2021 Earnings Call
Revenue
$3.66M*
Gross margin
73.1%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
CVRx, Inc. Q3 FY2021 Earnings Call
Revenue
$3.40M
▲ 240.5% YoY
Diluted EPS
$-0.30
Gross margin
74.2%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
CVRx, Inc. Q2 FY2021 Earnings Call
Revenue
$3.12M
▲ 149.8% YoY
Diluted EPS
$-48.48
Gross margin
70.8%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts CIK 1235912 CUSIP 126638105 13F (30d) 87 filings 86 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)